tanshinone has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valipour, M | 1 |
| Al-Karmalawy, AA; Darwish, KM; Elhady, SS; Elmaaty, AA; Hamed, MIA; Khattab, M; Salah, M; Saleh, MM | 1 |
1 review(s) available for tanshinone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS-CoV-2-induced CNS complications.
Topics: COVID-19; Humans; p38 Mitogen-Activated Protein Kinases; SARS-CoV-2 | 2023 |
1 other study(ies) available for tanshinone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |